Valuation: PharmaEngine, Inc.

Market Cap 7.54B 229M 208M 193M 174M 328M 21.36B 341M 2.33B 920M 11.53B 858M 840M 36.41B P/E 2026 *
14.1x
P/E 2027 * 14.7x
Enterprise Value 7.54B 229M 208M 193M 174M 328M 21.36B 341M 2.33B 920M 11.53B 858M 840M 36.41B EV / Sales 2026 *
7.46x
EV / Sales 2027 * 7.38x
Free-Float
61.29%
Yield 2026 *
-
Yield 2027 * -
1 day+1.94%
Current month-9.79%
1 month-8.54%
3 months-11.02%
6 months-3.49%
Current year-25.43%
1 week 51.2
Extreme 51.2
54.8
1 month 49.5
Extreme 49.5
58.4
Current year 49.5
Extreme 49.5
74
1 year 49.5
Extreme 49.5
74.4
3 years 49.5
Extreme 49.5
123
5 years 49.5
Extreme 49.5
150.5
10 years 33.1
Extreme 33.1
197
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2021-05-16
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2018-01-18
Director/Board Member - 2018-05-14
Director/Board Member - 2019-06-12
Change 5-day change 1-year change 3-year change Capi.($)
+1.94%0.00%-27.88%-48.78% 225M
-1.34%-3.09%+56.10%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.01% 58.86B
+0.54%+0.45%+25.96%+87.77% 55.22B
-2.34%-3.90%+10.90%+115.97% 47.21B
+0.09%-6.08%+18.67%+25.90% 42.45B
-2.58%+0.24%+18.54%+41.28% 36.44B
-1.76%-11.56%+126.44%+649.27% 35.19B
-0.17%-1.83%+82.46%+57.69% 32.66B
-1.69%-0.79%-40.58%+382.68% 26.73B
Average -0.67%-3.63%+27.96%+147.06% 40B
Weighted average by Cap. -0.84%-3.64%+34.18%+143.87%

Financials

2026 *2027 *
Net sales 1.01B 30.64M 27.94M 25.84M 23.32M 43.91M 2.86B 45.64M 312M 123M 1.55B 115M 113M 4.88B 1.02B 30.97M 28.25M 26.12M 23.57M 44.39M 2.89B 46.14M 315M 125M 1.56B 116M 114M 4.93B
Net income 534M 16.18M 14.76M 13.65M 12.31M 23.19M 1.51B 24.11M 165M 65.15M 816M 60.71M 59.44M 2.58B 511M 15.49M 14.12M 13.06M 11.78M 22.19M 1.45B 23.07M 158M 62.34M 781M 58.1M 56.88M 2.47B
Net Debt - -
Projected Income Statement - Annual - PharmaEngine, Inc.
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
26-11-18 NT$52.50 +1.94% 348,350
26-11-17 NT$51.50 -2.46% 353,391
26-11-16 NT$52.80 -3.12% 254,202
26-11-13 NT$54.50 +2.83% 221,770
26-11-12 NT$53.00 +0.95% 202,033
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - PharmaEngine, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
52.50
Average target price
-
  1. Stock Market
  2. Stocks
  3. 4162 Stock